A free teleconference series offered by UsAgainstAlzheimer's Network covering a wide range of topics with leaders in the Alzheimer's community.
Dr. Howard Fillit joined George Vradenburg for this month’s Alzheimer’s Talks to discuss a new report he co-authored, “Single Endpoint for New Drug Approvals for Alzheimer’s Disease”. The report proposes a change in how we define a clinically meaningful drug and therefore the framework for FDA approvals of a possible Alzheimer’s treatment.
It’s time to change the way we measure a drug’s effectiveness.
Standards were set based on decades-old knowledge, and drugs were deemed effective if there were improvements in both cognition and function, co-primary endpoints.
Several advances mean standards need to change.
New developments in biomarkers, such as PET scans, mean that scientists can now determine, with certainty, if someone has Alzheimer’s disease or not. This was not the case 40 years ago. Now, when people take part in clinical trials, we know they have Alzheimer’s disease and the results of the trials are much more relevant.
We have to set realistic expectations.
If we don’t create realistic expectations for the clinical meaningfulness of a drug, we may reduce investment in research. The voice of the patient and caregiver is also crucial to determine what is clinically meaningful.
Other drugs, for conditions such as heart disease, have a single primary endpoint. For Alzheimer’s disease, composite cognition might be the only clinical primary endpoint needed in certain drug trials as there is a fairly linear relationship between loss of cognition and loss of function. A modernization of standards for Alzheimer’s drugs, to make them meaningful and approvable, is necessary.
Prevention is a priority.
Improvements in public health have reduced risk factors. For example, more exercise, better diets, and better management of hypertension and diabetes have been shown to reduce Alzheimer’s risk.
The Alzheimer’s Drug Discovery Foundation has a website called Cognitive Vitality that evaluates the efficacy, safety, and evidence of possible preventions, including supplements and diets.
If you missed the talk—or if you’d like to hear it again—you can listen to an audio playback or read the transcript of the conversation.
Author and journalist Greg O’Brien spoke about his journey into Alzheimer’s disease with Meryl Comer. Greg was diagnosed with early onset Alzheimer’s in 2009, and has been writing, chronicling, and talking about the process ever since. He shared his thoughts, strategies, and experiences in a candid and personal conversation.
Greg’s book, On Pluto, Inside the Mind of Alzheimer’s, has been described as “heartbreaking, defiant, profound” and a new edition will be released this summer. He also has started a podcast series with UsAgainstAlzheimer’s, also called On Pluto.
A few key highlights:
As someone who has Alzheimer’s, Greg shared these tips and strategies to others who have also been diagnosed with, or are progressing with the disease:
- Don’t be afraid to ask questions.
- Be willing to give up control over certain things, but hold on to your essence and strengths.
- Physical exercise can really help reboot the brain.
- Talk about the disease with your family and your community.
- Get involved in clinical trials, telling your story, or advocacy. It will help you realize that you are not alone.
If you are a caregiver with a loved one who has Alzheimer’s, from Greg’s perspective, these are some things that can really make a difference:
- It’s not what you say, but how you say it. Body language and keeping your body calm can help a person who may be frustrated or angry.
- Don’t challenge a question; just go with the disease.
- Say “we” instead of “you” when trying to solve problems.
- Be aware that sundown may be the most difficult time of the day and plan ahead for that.
- Acknowledge your own anger and frustration.
Thank you to Greg O’Brien for talking about his journey with Alzheimer’s. If you missed the talk – or if you’d like to hear it again – you can listen to an audio playback, read the transcript of our conversation, or check out the Storify recap.
Debra Lappin was the guest host for our March Alzheimer’s Talks. She spoke with Dr. Gregory Jicha, Professor of Neurology and the holder of the Robert T. and Nyles Y. McCowan Endowed Chair in Alzheimer’s Disease at the Sanders-Brown Center on Aging at the University of Kentucky Alzheimer’s Disease Center.
Dr. Jicha talked about the impact of genetics on Alzheimer’s risk, how genetic research is affecting the development of medicines, and why individuals with risk genes are important for clinical trials.
A few key highlights:
Risk genes have been identified
Researchers have identified at least eighteen genes that put you at a higher risk for Alzheimer’s. Dr. Jicha stressed that having a risk factor gene does not mean you will definitely come down with Alzheimer’s; also, if you don’t have one of those genes, you could still develop Alzheimer’s so its best to do everything we can for our brain health.
These discoveries help researchers better understand how Alzheimer’s takes hold in the brain, and gives them a “road map” of how medicines might slow, stop, prevent, or perhaps someday even reverse Alzheimer changes in the brain.
Genetics can help personalize medicine
Genes can also help predict a patient’s response to medicines. An individual’s genes can make some medicines more effective or others more risky, so genetic information could help doctors prescribe the best medicines for each individual.
Genetic testing will move the research forward
Though genetic testing is not available commercially for all of the risk factor genes, there are tests available for the genes that may put you at the highest risk for Alzheimer’s. People interested in genetic testing should consult their doctors or genetic counselors.
Clinical trial participation is crucial
Clinical trials could be helped by having genetic information from individuals who carry risk factor genes, especially if they are identified before they develop symptoms of memory impairment.
Getting involved in research is something we can all do to speed the search for a treatment. If you are interested in clinical trials, some places for you to check out include:
Thank you to Dr. Jicha for talking about the links between Alzheimer’s and genetics. If you missed the talk – or if you’d like to hear it again – you can listen to an audio playback or read the transcript of our conversation.
For our February Alzheimer’s Talks, guest host Meryl Comer talked with Dr. Nathan Rose, Assistant Professor of Cognition Brain and Behavior in the Department of Psychology at the University of Notre Dame. Dr. Rose’s research focuses on basic memory processes and how these processes break down in aging and Alzheimer’s disease. He shared with us two exciting areas of his memory research that have earned his team a lot of media attention recently.
A few key highlights:
Locating missing memory
Dr. Rose and his team are helping us better understand how the brain processes short-term memory through neuroimaging techniques. They found that some working memories, once thought to be forgotten, were actually still present though neuroimaging techniques had been unable to see activity for these types of memory. When Dr. Rose used TMS, or transcranial magnetic stimulation, to ping or trigger brain areas associated with these silent memories, neural activity increased and the lost working memories were briefly reactivated. This research provides a shift in understanding of working memory and short-term retention. Dr. Rose is currently studying healthy people to better understand how the brain works, and future research will look at how those mechanisms break down in aging and conditions like Alzheimer’s.
Remembering to remember
Prospective memory is remembering to remember to do something at the appropriate time in the future (ex. taking medicine at bedtime). This ability is often lost for those with Alzheimer’s disease and affects the ability to live independently.
Dr. Rose and his team have developed a game called Virtual Week to help people work on strategies to strengthen prospective memory. His research has shown that people not only improved at the game, but also improved at performing instrumental activities of daily living and remembering to remember outside the lab. The game has been so popular that he is developing an app to bring it to a wider audience.
Thank you to Dr. Rose for talking about his research on memory. If you missed the talk – or if you’d like to hear it again – you can listen to an audio playback. We look forward to having you join the next Alzheimer's Talks on March 17th with Dr. Gregory Jicha from the Sanders-Brown Center on Aging at the University of Kentucky Alzheimer's Disease Center.
For the first Alzheimer’s Talks of 2017, we were joined by Dr. Scott Turner of Georgetown University to discuss a fascinating new clinical trial that repurposes an existing drug.
Dr. Turner is one of the nation’s foremost clinical researchers in Alzheimer’s and is Professor of Neurology at Georgetown University Medical Center, medical co-director of Georgetown Translational Neurotherapeutics Program and Director of the Memory Disorders Program.
Here are a few key highlights from the call:
Drug repurposing could help us find a treatment more quickly
If a drug is already available for prescription, we know a lot about its safety and tolerability and therefore can accelerate the process to try it for another disease.
Could a cancer drug possibly be a treatment for Alzheimer’s disease?
This exciting clinical trial repurposes a cancer drug, nilotinib, as a possible treatment for Alzheimer’s disease, and a parallel study repurposes the same drug for Parkinson’s disease. The drug promotes autophagy – convincing a cell to promote self-digestion of toxic protein aggregates in nerve cells in the brain. In animal studies and a small pilot study with 11 Parkinson’s patients, the drug was safe and looked promising but this could be due to the placebo effect, which is why this study is needed.
Phase two trial for Alzheimer’s disease now recruiting at Georgetown University
The investigators are looking for a volunteer to join the study every week between now and November. The study being conducted at Georgetown will require approximately 15 visits during a 12 month period. If you have a diagnosis of mild to moderate Alzheimer’s disease and are interested in learning more, information can be found at: memory.georgetown.edu.
Philanthropy is important for research
This study is being funded by a grant from the Alzheimer’s Drug Discovery Foundation (ADDF) along with private philanthropists.
UsAgainstAlzheimer’s has a goal to find a treatment faster by reducing the time and cost of clinical trials. We hope that by featuring some clinical trials that are recruiting participants we share with you the most up to date information on the science from leading Alzheimer’s researchers and also hope that you might be interested in participating, something that we can all do to help find a cure.
If you missed the talk, or would like to hear it again, you can listen to the recording or read the transcript.